Department of Obstetrics and Gynecology, Medical University of Graz , Graz , Austria.
Center for Medical Research, Medical University of Graz , Graz , Austria.
Am J Physiol Endocrinol Metab. 2019 Mar 1;316(3):E347-E357. doi: 10.1152/ajpendo.00320.2018. Epub 2018 Nov 13.
Human milk oligosaccharides (HMOs) are bioactive glycans linked with health benefits to both the breast-fed infant and lactating mother. We hypothesized that HMOs are present before lactation, already during pregnancy, and are influenced by maternal body composition. In a pilot study, we investigated individual and temporal variations in HMO composition and concentration in maternal serum at gestational weeks 10-14 ( visit 1), 20-24 ( visit 2), and 30-35 (visit 3) (V1, V2, and V3, respectively) and associations with maternal body composition. HMOs were quantified by HPLC and confirmed by enzymatic digest and mass spectrometry. Associations of maternal prepregnancy body mass index (BMI), subcutaneous adipose tissue (SAT) thickness, and adipokines with absolute and relative HMO concentrations were analyzed by Spearman correlation. We identified 16 HMOs and 2 oligosaccharides not common to human milk. HMO concentration and composition varied with gestational age and secretor status. HMO concentration increased with gestational age and changed from a predominantly sialylated profile at V1 to a more balanced fucosylated-to-sialylated ratio at V3, mostly due to a profound increase in 2'-fucosyllactose (2'-FL), reflecting secretor phenotype. In secretor-positive women, BMI was negatively correlated with 2'-FL at V2. SAT at V1 and V2 were strongly negatively correlated with 2'-FL concentrations. This pilot study shows that prenatal HMOs are present in maternal serum, suggesting roles for HMOs already during pregnancy. Our result that maternal body composition is associated with prenatal HMOs might indicate that maternal metabolism modulates HMO composition with unknown implications for maternal and fetal health already during pregnancy.
人乳寡糖(HMOs)是与母乳喂养婴儿和哺乳期母亲健康益处相关的生物活性糖。我们假设 HMOs 在哺乳期前、妊娠期间就已经存在,并受母体身体成分的影响。在一项初步研究中,我们研究了孕妇血清中 HMO 组成和浓度的个体和时间变化,在妊娠 10-14 周(第 1 次访视,V1)、20-24 周(第 2 次访视,V2)和 30-35 周(第 3 次访视,V3)时进行了测量。我们通过 HPLC 定量 HMO,并通过酶消化和质谱进行确认。通过 Spearman 相关分析,研究了母体孕前体重指数(BMI)、皮下脂肪组织(SAT)厚度和脂肪因子与绝对和相对 HMO 浓度的相关性。我们鉴定了 16 种 HMO 和 2 种在人乳中不常见的寡糖。HMO 浓度和组成随孕龄和分泌状态而变化。HMO 浓度随孕龄增加而增加,从 V1 时主要为唾液酸化谱转变为 V3 时更为平衡的岩藻糖基化到唾液酸化比值,主要是由于 2'-岩藻糖基乳糖(2'-FL)的显著增加,反映了分泌表型。在分泌阳性妇女中,V2 时 BMI 与 2'-FL 呈负相关。V1 和 V2 时的 SAT 与 2'-FL 浓度呈强烈负相关。这项初步研究表明,产前 HMOs 存在于母体血清中,表明 HMOs 在妊娠期间已经发挥作用。我们的研究结果表明,母体身体成分与产前 HMOs 相关,这可能表明母体代谢调节 HMO 组成,而这对妊娠期间的母体和胎儿健康可能具有未知的影响。